234 related articles for article (PubMed ID: 32924092)
1. Updating the Cost Effectiveness of Oral Anticoagulants for Patients with Atrial Fibrillation Based on Varying Stroke and Bleed Risk Profiles.
Wang CY; Pham PN; Thai TN; Brown JD
Pharmacoeconomics; 2020 Dec; 38(12):1333-1343. PubMed ID: 32924092
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.
Shah A; Shewale A; Hayes CJ; Martin BC
Stroke; 2016 Jun; 47(6):1555-61. PubMed ID: 27103018
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation.
Reddy VY; Akehurst RL; Amorosi SL; Gavaghan MB; Hertz DS; Holmes DR
Stroke; 2018 Jun; 49(6):1464-1470. PubMed ID: 29739915
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding.
Rattanachotphanit T; Limwattananon C; Waleekhachonloet O; Limwattananon P; Sawanyawisuth K
Pharmacoeconomics; 2019 Feb; 37(2):279-289. PubMed ID: 30387074
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
Hernandez I; Smith KJ; Zhang Y
Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008
[TBL] [Abstract][Full Text] [Related]
6. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Analysis of Direct Oral Anticoagulants Vs. Vitamin K Antagonists in the Elderly With Atrial Fibrillation: Insights From the Evidence in a Real-World Setting.
Wu Y; Zhang C; Gu ZC
Front Cardiovasc Med; 2021; 8():675200. PubMed ID: 34268343
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients.
Walter E; Voit M; Eichhober G
Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):265-275. PubMed ID: 32700584
[TBL] [Abstract][Full Text] [Related]
9. [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
Rudakova AV; Tatarskiĭ BA
Kardiologiia; 2014; 54(7):43-52. PubMed ID: 25177813
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of antithrombotic agents for atrial fibrillation in older adults at risk for falls: a mathematical modelling study.
Wong EKC; Belza C; Naimark DMJ; Straus SE; Wijeysundera HC
CMAJ Open; 2020; 8(4):E706-E714. PubMed ID: 33158928
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia.
Hersi AS; Osenenko KM; Kherraf SA; Aziz AA; Sambrook RJ
Ann Saudi Med; 2019; 39(4):265-278. PubMed ID: 31381381
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Chevalier J; Delaitre O; Hammès F; de Pouvourville G
Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation.
Wang Y; Xie F; Kong MC; Lee LH; Ng HJ; Ko Y
Cardiovasc Drugs Ther; 2014 Dec; 28(6):575-85. PubMed ID: 25319314
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control.
Janzic A; Kos M
Pharmacoeconomics; 2015 Apr; 33(4):395-408. PubMed ID: 25512096
[TBL] [Abstract][Full Text] [Related]
18. Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding.
Hospodar AR; Smith KJ; Zhang Y; Hernandez I
Am J Cardiovasc Drugs; 2018 Aug; 18(4):317-325. PubMed ID: 29740750
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation in mainland China.
Zhou H; Nie X; Jiang M; Dong W
J Clin Pharm Ther; 2022 Apr; 47(4):523-530. PubMed ID: 34783090
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease.
Ruiz Vargas E; Sposato LA; Lee SAW; Hachinski V; Cipriano LE
Stroke; 2018 Dec; 49(12):2844-2850. PubMed ID: 30571418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]